Large Nanofacility at the University of Chicago

Large Nanofacility at the University of Chicago

The Pritzker Foundation provided a generous a $15 million gift to develop the 10,000 square foot large nanofacility for the University of Chicago. The National Science Foundation provided an additional $5 million to establish the Soft and Hybrid Nanotechnology Experimental Resource, a partnership between UChicago and Northwestern University.

Magnetic Biocompatible Photonic Crystals can be used both for Optics and Medicine

Magnetic Biocompatible Photonic Crystals can be used both for Optics and Medicine

Researchers at ITMO University developed a new approach for obtaining non-toxic magnetic photonic crystals, expanding their applications from mainly photonics to biomedicine. Nanospheres made with the new method may be used for designing drugs to fight thrombosis and cancer.

Clinical Trial Services and High-Potency Compounds

Clinical Trial Services and High-Potency Compounds

Capsugel, now a Lonza company, a global leader in delivering high-quality, innovative dosage forms and solutions, today announced expanded clinical trial capabilities, as well as increased development and manufacturing capabilities for specialized drug products utilizing liquid-filled hard capsule (LFHC) technology, at its Edinburgh facility in Scotland.

Novartis plans acquisition of Advanced Accelerator Applications

Novartis plans acquisition of Advanced Accelerator Applications

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender offer for 100% of the share capital of AAA subject to certain conditions. Advanced Accelerator Applications (NASDAQ:AAAP) is a radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicines including Lutathera®

AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain

AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain

AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain. The US Food and Drug Administration (FDA) has granted priority review to AbbVie’s investigational candidate, elagolix, for the management of endometriosis with associated pain. Endometriosis is characterised by long-term pelvic pain and caused by tissue growth outside of the uterus.

Cleanroom News